Dermatology最新文献

{"title":"Abnormalities in Pulmonary Function Tests in Patients with Psoriasis.","authors":"Mateusz Mleczko, Maciej Zakrzewski, Agnieszka Gerkowicz, Jerzy Mosiewicz, Dorota Krasowska","doi":"10.1159/000548175","DOIUrl":"https://doi.org/10.1159/000548175","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is associated with lung diseases, but there have been no studies on full pulmonary function tests (PFTs) in patients with psoriasis. The aim of this study was to compare pulmonary function measurements in patients with psoriasis and controls.</p><p><strong>Methods: </strong>Sixty-eight patients with psoriasis and sixty-eight sex- and age-matched controls fulfilling the inclusion criteria were included in this study. Spirometric pulmonary function testing, body plethysmography, and DLCO testing were performed on all study participants.</p><p><strong>Results: </strong>The mean FEV1/FVC ratio was significantly lower in the psoriasis patients than in the controls (98 ± 6.6 vs. 100.3 ± 3.2, p < 0.05). In the subgroup analysis, the FEV1/FVC ratio in non-smoking and non-obese subjects was significantly lower in psoriasis patients than controls (98.2 ± 5 vs. 100.6 ± 2.7; p < 0.05 and 98 ± 6.8 vs. 100 ± 3.1; p < 0.05, respectively). There was no statistically significant difference in body plethysmography or the DLCO test parameters between groups.</p><p><strong>Conclusion: </strong>Psoriasis patients had a lower mean FEV1/FVC ratio compared to the control subjects. The FEV1/FVC ratio was independently associated with the presence of psoriasis.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-16"},"PeriodicalIF":2.7,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Angiopausin® and Angiopoietin: Unveiling New Mechanisms in Rosacea Treatment through Kinetic Erythema Analysis with the AAREA® Algorithm.","authors":"Rayan Arnaout, Oliver Sorg, Nathalie Satta, Cathy Seilaz, Martine von Englebrechten, Jean-Hilaire Saurat","doi":"10.1159/000547545","DOIUrl":"https://doi.org/10.1159/000547545","url":null,"abstract":"<p><strong>Introduction: </strong>Non-transient erythema (NTE) is a major feature of rosacea, but its clinical evaluation is subject to human investigator variability. The angiopoietin-TIE2 receptor tyrosine kinase pathway plays a key role in regulating vascular homeostasis, but was previously overlooked as a target for rosacea therapy. Angiopausin® is a patented plant-based ingredient identified through a molecular phytotherapy screening program as a positive inducer of the angiopoietin-TIE2 pathway, which is the \"gatekeeper of vascular quiescence.\" The objective of this preliminary study was to compare traditional clinical NTE scoring methods with a novel algorithm-assisted approach (AAREA®) aimed at both assessing erythema and exploring the potential scientific interest of analyzing erythema regression patterns in patients with rosacea treated with topical Angiopausin.</p><p><strong>Methods: </strong>Data were obtained from the regular follow-up of patients with mild-to-moderate rosacea, monitored as part of the real-world \"homeostasis in chronic facial dermatosis\" registry cohort. Patients were managed exclusively with Angiopausin (applied twice daily) for up to 64 weeks. Facial redness was evaluated clinically using the global investigator erythema assessment (IEA) score and compared to data generated using the algorithm-assisted approach using an ANOVA with post hoc Tukey tests.</p><p><strong>Results: </strong>Forty-four patients (9 men, 35 women) were included (average follow-up: 29 ± 3 weeks per patient). Reductions in total IEA scores were observed at week 4 (W4; p < 0.05) and through W8 to W64 (p < 0.001). Decreases in individual scores were also observed for flushing, NTE and edema (W4 to W64: p < 0.001), and telangiectasia (W8 to W32; p < 0.001). A high level of agreement (R2 = 0.9566) was observed between the clinical IEA scores and the algorithm-assisted approach. The algorithm-assisted approach also provided quantitative data on redness area and intensity, detected early reductions in NTE, and identified distinctive NTE regression patterns.</p><p><strong>Conclusion: </strong>This study demonstrated the real-world effectiveness of targeting the angiopoietin-TIE2 pathway for managing rosacea, with topical Angiopausin resulting in significant and long-lasting reductions in NTE and other vascular manifestations. It also highlighted how advances in rosacea therapy can be studied by profiling the clinical effects of treatments using artificial intelligence. The AAREA tool provided valuable data for clinical scoring and research into understanding rosacea pathogenesis.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-10"},"PeriodicalIF":2.7,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145005978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Importance of Reader Studies in Dermatology.","authors":"Frank Zelun Jing, Alexander Meves","doi":"10.1159/000548165","DOIUrl":"10.1159/000548165","url":null,"abstract":"","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-2"},"PeriodicalIF":2.7,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"X-Ray therapy of Skin Cancer at Critical Facial Sites: Results of a tertiary referral centre.","authors":"Sophie Tschopp, Amélie Ciernik, Reinhard Dummer, Laurence Imhof","doi":"10.1159/000548154","DOIUrl":"https://doi.org/10.1159/000548154","url":null,"abstract":"<p><strong>Background: </strong>Therapeutic management of skin cancer (SC) in the \"H-area\" of the face is challenging due to the demands of function, cosmesis, and efficacy.</p><p><strong>Objective: </strong>To evaluate the efficacy and safety of superficial radiotherapy (RT) for skin cancer in the \"H-area\" of the face and to identify predictors of recurrence.</p><p><strong>Methods: </strong>Retrospective analysis of patients with SC in the \"H-area\" of the face treated with superficial RT at the University Hospital of Zurich, Switzerland, between 2010 and 2021. The study included cases of basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and in situ SCC (isSCC), lentigo maligna melanoma (LMM), lentigo maligna (LM), and primary cutaneous T/B-cell lymphoma (pcTCL and pcBCL).</p><p><strong>Results: </strong>We identified 550 lesions in 382 patients. Estimated relapse rates at 5 years were lowest for SCC (3.2%), isSCC (1.9%), and BCC (9.7%), while LMM and LM showed estimated relapse rates of 28.9% and 35.0%, respectively. Significant predictive factors for overall recurrence were increased Common Terminology Criteria for Adverse Events (CTCAE) grades with a Hazard Ratio (HR) of 1.9 (1.1-3.4), and the treatment of secondary lesions with a HR of 2.6 (1.4-5.1).</p><p><strong>Conclusion: </strong>RT is a valuable treatment option for malignant skin tumors, especially NMSC, in high-risk areas, including the facial 'H-area', providing favorable results with minimal side effects.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-22"},"PeriodicalIF":2.7,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No Change in HbA1c Levels during Treatment with Biologics or Methotrexate in Patients with Psoriasis.","authors":"Maheen Fatima Bukhari, Christopher Willy Schwarz, Claus Otto Carl Zachariae, Nikolai Loft, Lone Skov","doi":"10.1159/000547591","DOIUrl":"10.1159/000547591","url":null,"abstract":"<p><strong>Introduction: </strong>Biological treatment has been associated with changes in blood glucose levels in different populations of patients with immunological diseases, although studies report conflicting results. This study aimed to investigate changes in blood glucose levels during treatment with biologics and methotrexate as the control, through changes in hemoglobin A1c (HbA1c) levels.</p><p><strong>Method: </strong>In this study, the HbA1c levels at baseline and after 1 year of treatment were compared using Wilcoxon's signed-rank test. The following treatments were considered: TNF-α inhibitors (TNFi) (adalimumab and infliximab), IL-17 inhibitors (IL-17i) (brodalumab, ixekizumab, and secukinumab), IL-12/23 inhibitor (IL-12/23i) (ustekinumab), IL-23 inhibitors (IL-23i) (guselkumab and risankizumab), and methotrexate.</p><p><strong>Results: </strong>In total, 386 patients with psoriasis were included: adalimumab (n = 166), infliximab (n = 7), brodalumab (n = 19), ixekizumab (n = 35), secukinumab (n = 44), ustekinumab (n = 42), guselkumab (n = 11), risankizumab (n = 7), and methotrexate (n = 55). For all groups of biologics and methotrexate, no statistically or clinically significant changes in HbA1c levels were observed. In a sensitivity analysis including only patients in the upper quartile of baseline HbA1c (36-47 mmol/mol) treated with TNFi, IL-17i, or methotrexate, no significant change in HbA1c levels was observed after 1 year of treatment.</p><p><strong>Conclusion: </strong>In a group of patients with psoriasis and normal baseline glucose levels, treatment with biologics or methotrexate for 1 year did not appear to affect blood glucose levels as measured by HbA1c. This could indicate that the treatments lack antidiabetic properties.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-6"},"PeriodicalIF":2.7,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Baricitinib in the Treatment of Severe Alopecia Areata in Pediatric Patients: Data from Real-Clinical Practice.","authors":"Dandan Wei, Dan Huang, Shufen Wang, Wenyu Li, Hongdi Xiong, Sijian Wen","doi":"10.1159/000547786","DOIUrl":"10.1159/000547786","url":null,"abstract":"<p><strong>Introduction: </strong>Alopecia areata (AA) is an autoimmune disorder with a higher prevalence in pediatric patients than adults, but treatment options remain limited. Baricitinib, a Janus kinase (JAK)-1/2 inhibitor, has shown efficacy in adults with severe AA, yet data on its use in pediatric patients are limited.</p><p><strong>Methods: </strong>This study included pediatric patients (ages 2-18) with severe AA (Severity of Alopecia Tool [SALT] ≥50) treated with baricitinib for at least 3 months between January 2023 and October 2024. Demographics, SALT scores before and after treatment, and adverse events were collected.</p><p><strong>Results: </strong>Thirty-three patients were included, with a mean age of 9.93 years and average disease duration of 23.44 months. Sixteen patients received 2 mg and 17 received 4 mg of baricitinib. At baseline, 54.5% had a SALT score above 90. After treatment, 45.5% of patients had a 50% reduction in their SALT score. The average treatment duration was 6.5 months. Adverse events included elevated ALT (n = 1), acne (n = 1), and upper respiratory infection (n = 1), with no serious adverse events.</p><p><strong>Conclusion: </strong>Baricitinib demonstrated clinical efficacy and good tolerance in pediatric patients with severe AA.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-6"},"PeriodicalIF":2.7,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermoscopy and Reflectance Confocal Microscopy Improves Accuracy in Differentiating Atypical Basal Cell Carcinoma from Seborrheic Keratosis and Vice Versa.","authors":"Serena Morsia, Maria Antonietta Pizzichetta, Shaniko Kaleci, Johanna Chester, Silvana Ciardo, Antonio Alma, Dina Poplausky, Francesca Falcinelli, Jonas A Adalsteinsson, Pietro Rubegni, Emma Guttman-Yassky, Nicholas Gulati, Giovanni Pellacani, Elisa Cinotti, Francesca Farnetani","doi":"10.1159/000547590","DOIUrl":"10.1159/000547590","url":null,"abstract":"<p><strong>Introduction: </strong>To differentiate basal cell carcinomas (BCCs) and seborrheic keratoses (SKs) with reciprocal dermoscopic mimicking features is challenging. The aim of this study was to identify dermoscopic BCC and SK criteria predictive of diagnosis among reciprocal mimicking features and to evaluate the impact of adjunctive reflectance confocal microscopy (RCM).</p><p><strong>Methods: </strong>A multicenter study with retrospective evaluation of images was conducted by 3 dermatologists, blinded to histology. Histologically confirmed lesions with a complete set of clinical, dermoscopy, and RCM images with ≥1 reciprocal dermoscopy features were selected.</p><p><strong>Results: </strong>A total of 231 dermoscopy and RCM evaluations were included. No demographic differences between patients were observed. Independent dermoscopic diagnostic features revealed shiny white-red structureless areas (OR = 2.3, CI: 1.1-4.8, p = 0.023), maple leaf-like areas (OR = 2.2, CI: 1.0-4.9, p = 0.044), arborizing vessels (OR = 2.2, CI: 1.0-4.7, p = 0.049), and blue-gray globules (OR = 2.0, CI: 1.0-3.9, p = 0.041) for BCC and milia-like cysts (OR = 0.4, CI 0.2-0.9, p = 0.041), hairpin vessels (OR = 0.3, CI: 0.1-0.5, p < 0.001), and coral-like pattern (OR = 0.2, CI: 0.05-0.7, p = 0.018) for SK diagnoses. All BCC-specific RCM criteria were more prevalent in BCCs (p < 0.001) and all SK-specific RCM criteria were more prevalent in SKs (p < 0.001), with the exception of dilated loop vessels.</p><p><strong>Conclusion: </strong>Despite the identification of independent dermoscopy criteria, diagnosis remains complex. Adjunctive RCM assists in the differential diagnosis.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-10"},"PeriodicalIF":2.7,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of Pruritus: Global Burden of Disease Research from 1990 to 2021 and Future Trend Predictions.","authors":"Zirui Wang, Shuai Han, Xiaoshan Huang, Benmeng Wu, Chunyan Mei, Hui Liu, Min Wu","doi":"10.1159/000547821","DOIUrl":"10.1159/000547821","url":null,"abstract":"<p><strong>Introduction: </strong>Pruritus, the most common dermatological symptom, lacks comprehensive global epidemiological data. This study analyzed pruritus trends from 1990 to 2021 using the Global Burden of Disease (GBD) 2021 dataset to inform prevention strategies.</p><p><strong>Methods: </strong>Data on pruritus incidence, prevalence, and disability-adjusted life years were extracted. Temporal trends were assessed using joinpoint regression, while age-period-cohort modeling evaluated age, period, and cohort effects. Socio-demographic index (SDI) correlations and future trends were analyzed using spline models and autoregressive integrated moving average projections.</p><p><strong>Results: </strong>In 2021, 80.65 million individuals (95% uncertainty interval: 72.30-89.30 million) were affected by pruritus, with 62.53 million new cases (95% confidence interval [CI]: 55.87-70.33 million), doubling since 1990. The age-standardized prevalence rate (ASPR) and age-standardized incidence rate (ASIR) showed annual increases of 0.3352% (95% CI: 0.3247-0.3456) and 0.3168% (95% CI: 0.3063-0.3272), respectively. Higher SDI regions had lower pruritus burdens. The highest risk occurred in the 80-84 age group, with incidence and cohort effects steadily rising. By 2050, ASIR, ASPR, and ASDR are projected to reach 939.33, 1194.41, and 12.52 for females, and 716.82, 933.25, and 9.90 for males.</p><p><strong>Conclusion: </strong>Pruritus burden has steadily increased over 3 decades, with the elderly most affected. As the global population ages, targeted strategies are essential to mitigate its growing impact.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-10"},"PeriodicalIF":2.7,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographics, Comorbidity, Treatment, Healthcare Resource Utilization, and Costs Analysis of Hidradenitis Suppurativa in Dubai.","authors":"Anwar Al Hammadi, Samir Hantirah, Ashraf Mohamed Reda, Mohamed Farghaly, Falk Bechara, Saad Ehab, Dayane Daou, Amal Masalmeh, Kumaresan Subramanyam, Badarinath Chickballapur Ramachandrachar, Ashok Natarajan","doi":"10.1159/000545025","DOIUrl":"10.1159/000545025","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic, inflammatory, and debilitating skin disorder with a substantial disease burden. Currently, there is a dearth of information regarding healthcare resource utilization (HCRU) and treatment patterns for patients with HS in Dubai. A better understanding of disease demographics and patient characteristics are necessary for reducing the healthcare costs. The current study evaluated the disease burden, treatment patterns, HCRU, and associated costs in patients with HS, in Dubai, United Arab Emirates (UAE).</p><p><strong>Methods: </strong>This secondary, longitudinal, retrospective, single-cohort study was conducted from January 1, 2014 to December 31, 2021. Dubai Real-World Claims Database (DRWD) was used for patients' information. Study included patients with first diagnosis claim during the index period and had continuous enrollment. Patients who did not have continuous enrollment were excluded from the study. Study population was identified based on International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code L73.2. Patients' demographics, common comorbidities, treatment patterns, specialty analysis, HCRU, and in patient length of stay were investigated.</p><p><strong>Results: </strong>The study included 13,180 patients (median age: 37 years), with similar gender distribution (male: 50.4%; female: 49.6%). The overall reported cases of HS (2015-2021) were in the range of 1,350 to 3,719. Type 2 diabetes mellitus was the most common comorbidity (59.0%). Topical and systemic antibiotics were most frequently prescribed medications (79.6%), followed by systemic and topical anti-acne medications (27.7%) and non-steroidal anti-inflammatory drugs (27.2%). Overall HCRU and associated costs increased by 76.9% from 12-month pre-index period to 12-month post-index period. Disease-specific median healthcare costs contributed largely (79.5%) to the overall healthcare costs. In the post-index period, contribution of disease-specific median healthcare costs to all-cause median healthcare costs was highest for diagnosis-related group (97.9%), followed by consumables (88.4%), procedures (37.5%), services (27.6), and medications (25.4%).</p><p><strong>Conclusion: </strong>HS is well-documented disease in Dubai claims data and is associated with significant morbidity and healthcare costs. This sheds light on the high burden of HS and should trigger increased awareness as well as new disease management interventions. Newer therapies such as biologics should play a role in the management of HS in the UAE.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-11"},"PeriodicalIF":2.7,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preparing for Polygenic Risk Scores in the Clinic: An Accessible Guide to Reading and Interpreting Genome-Wide Association Studies.","authors":"Faith Simmonds, Gregor B E Jemec, Lynn Petukhova","doi":"10.1159/000547616","DOIUrl":"10.1159/000547616","url":null,"abstract":"","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-4"},"PeriodicalIF":2.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}